Q-omics provides the consensus-scored COPS9 profile across patient tissues and cancer cell-line models. COPS9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, COPS9 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, COPS9 RNA expression shows 18,890 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where COPS9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COPS9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COPS9 survival associations across molecular data types. COPS9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COPS9 RNA expression–survival associations across cancer types. High COPS9 expression shows unfavorable associations in ACC, LIHC, SKCM, LGG, KICH and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for COPS9 RNA expression.
This table summarizes COPS9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for COPS9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COPS9 shows lower tumor expression in KICH and higher tumor expression in LIHC, COAD, UCEC, BRCA and CHOL. The KICH box plot shows higher COPS9 RNA expression in normal versus tumor tissue (log2 FC = −1.251, t-test p < 0.001).
This table shows molecular features associated with COPS9 in patient tissues and cancer cell lines. In patient samples, COPS9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, COPS9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
